Preferred Label : Spondyloarthropathy, susceptibility to, 1;
Symbol : SPDA1;
CISMeF acronym : SPDA1;
Type : Phenotype, molecular basis known;
Alternative titles and symbols : Ankylosing spondylitis, susceptibility to; Bechterew syndrome; Marie-strumpell spondylitis;
Description : Spondyloarthropathy (SpA), one of the commonest chronic rheumatic diseases, includes
a spectrum of related disorders comprising the prototype ankylosing spondylitis (AS),
a subset of psoriatic arthritis (PsA), reactive arthritis (ReA), arthritis associated
with inflammatory bowel disease, and undifferentiated spondyloarthropathy (Miceli-Richard
et al., 2004). These phenotypes are difficult to differentiate because they may occur
simultaneously or sequentially in the same patient. Studies have suggested that a
predominant shared component, including HLA-B27, predisposes to all phenotypic subsets,
and that these subsets should be considered as various phenotypic expressions of the
same disease (Said-Nahal et al., 2000, Said-Nahal et al., 2001). Braun and Sieper
(2007) provided a detailed review of ankylosing spondylitis, including clinical features,
pathogenesis, and management. - Genetic Heterogeneity of Susceptibility to Spondyloarthropathy
Additional susceptibility loci for spondyloarthropathy have been identified on chromosome
9q31-q34 (SPDA2; 183840) and chromosome 2q (SPDA3; 613238).;
Inheritance : Multifactorial;
Molecular basis : Susceptibility conferred by mutation in the major histocompatibility complex, class
I, B gene (HLA-B, 142830.0001);
Laboratory abnormalities : HLA-B27 haplotype association (95% patients); Rheumatoid factor negative;
Prefixed ID : #106300;
Origin ID : 106300;
UMLS CUI : C1862852;
Automatic exact mappings (from CISMeF team)
Currated CISMeF NLP mapping
DO Cross reference
HPO term(s)
Not associated HPO term(s)
ORDO concept(s)
Semantic type(s)